Bortezomib
Showing 51 - 75 of 1,116
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)
Active, not recruiting
- Lymphoma
- Relapsed/Refractory T-cell Lymphomas
- Romidepsin
- +2 more
-
Stanford, California
- +10 more
Feb 2, 2023
Plasma Cell Myeloma Trial in Worldwide (lenalidomide, bortezomib, cyclophosphamide)
Active, not recruiting
- Plasma Cell Myeloma
- lenalidomide
- +4 more
-
Nantes Cedex 01, France
- +11 more
May 3, 2022
Thrombotic Thrombocytopenic Purpura, Acquired Trial in Beijing (Bortezomib Injection)
Not yet recruiting
- Thrombotic Thrombocytopenic Purpura, Acquired
- Bortezomib Injection
-
Beijing, (Select), ChinaPeking Union Medical College Hospital
Nov 22, 2021
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- Bortezomib
-
Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022
Multiple Myeloma Trial in Denmark, Estonia, Norway (Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule)
Recruiting
- Multiple Myeloma
- Selinexor 20 MG Oral Tablet
- +3 more
-
Aalborg, Denmark
- +10 more
Apr 22, 2022
Multiple Myeloma Trial in Washington, Hackensack (Melphalan, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Melphalan
- Bortezomib
-
Washington, District of Columbia
- +1 more
May 6, 2022
Chemo-induced Peripheral Neuropathy, Plasma Cell Myeloma Trial in Winston-Salem (VascuTherm5 vascular compression device)
Recruiting
- Chemotherapy-induced Peripheral Neuropathy
- Plasma Cell Myeloma
- VascuTherm5 vascular compression device
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Dec 16, 2022
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Bortezomib
- Ruxolitinib
-
Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
Dec 3, 2021
Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)
Recruiting
- Multiple Myeloma
- Teclistamab (Tec)
- +4 more
-
Berlin, Germany
- +8 more
Jan 19, 2023
Breast Cancer Trial in Dallas (Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis)
Recruiting
- Breast Cancer
- Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
-
Dallas, TexasBaylor University Medical Center, Baylor Charles A Sammons Cance
Oct 7, 2021
HIV, Hematologic Malignancies Trial run by the National Cancer Institute (NCI) (RIC, GVHD prophylaxis, allo HCT)
Not yet recruiting
- HIV
- Hematologic Malignancies
- RIC
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)
Recruiting
- Multiple Myeloma
- anti-BCMA CAR-T
- VRD
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023
Maintenance With Bortezomib Plus Daratumumab After Induction
Recruiting
- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)
- Bortezomib
- Daratumumab
-
Arganda Del Rey, Spain
- +31 more
Sep 15, 2022
Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Isatuximab
- +4 more
-
Hamburg, Germany
- +3 more
Dec 16, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Los Angeles, California
- +1 more
Aug 19, 2022
Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Winship Cancer Institute
Nov 1, 2021
Multiple Myeloma Trial in Torino (velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade
Active, not recruiting
- Multiple Myeloma
- velcade subcutaneous melphalan prednisone
- +2 more
-
Torino, ItalyA.O.U. Città della Salute e della Scienza di Torino - SC Ematolo
Mar 24, 2022
Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)
Recruiting
- Plasma Cell Leukemia
- anti-BCMA CAR-T
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023
Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia Trial in Beijing (combination of a
Recruiting
- Autoimmune Hemolytic Anemia
- Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
- combination of a single dose anti-CD20 antibody and bortezomib
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 12, 2021
Multiple Myeloma Trial in United States (Bortezomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- +2 more
-
Denver, Colorado
- +7 more
Feb 11, 2022